Federal Register / Vol. 86, No. 33 / Monday, February 22, 2021 / Notices 10581 

Minerals, LLC (Prince) in Leesburg, 

Alabama meet the applicability criteria 

of NESHAP subparts BBBBBBB, 

CCCCCCC, and/or VVVVVV? 

A: Based on the information provided, 

EPA determines that Prince’s frit 

production processes meet the 

applicability criteria of subpart 

CCCCCCC and do not meet the 

applicability criteria for subparts 

BBBBBBB and VVVVVV. Subpart 

CCCCCCC is applicable to Prince’s 

facility because the subpart lists NAICS 

code 3255 and defines ‘‘paints and 

allied products manufacturing’’ as the 

production of paints and allied products 

(e.g., coatings) intended to ‘‘leave a 

dried film of solid material on a 

substrate,’’ and the subpart defines 

‘‘material containing HAP’’ as including 

any material containing nickel in 

amounts greater than 0.1 percent by 

weight. Subpart BBBBBBB defines 

‘‘chemical preparation’’ as being 

manufactured in a process described by 

the NAICS code 325998, so subpart 

BBBBBBB is not applicable. Subpart 

VVVVVV includes an applicability 

exclusion for sources subject to Subpart 

CCCCCCC, so subpart VVVVVV is not 

applicable. 

Abstract for [Z200005] 

Q: Does EPA approve an alternative 

monitoring plan (AMP) for six 

reciprocating internal combustion 

engines (RICEs) operating at less than 

100 percent maximum load during 

compliance testing at Kinder Morgan 

Natural Gas Pipeline’s Houston Central 

Gas Plant in Sheridan, Texas subject to 

NESHAP subpart ZZZZ? 

A: Yes. Based on the information 

provided, EPA conditionally approves 

an AMP to conduct performance testing 

for engines COMP–1, COMP–35, and 

COMP–13C at a maximum engine load 

of 85 percent with subsequent 

monitoring required at 85 percent plus 

or minus 10 percent load, and for 

engines COMP–349, COMP–350, and 

COMP–8 at a maximum engine load of 

90 percent with subsequent monitoring 

required at 90 percent plus or minus 10 

percent load. EPA agrees that these six 

RICEs cannot operate at 100 percent 

plus or minus 10 percent operational 

load during compliance testing as 

specified in 40 CFR 63.6620(b)(2) due to 

site-specific operations. If operations 

change such that the maximum load of 

the engines exceeds these alternative 

lower maximum loads, the AMP will 

become null and void and retesting at 

the higher engine load will be required 

to demonstrate compliance with subpart 

ZZZZ. 

John Dombrowski, 

Deputy Director, Office of Compliance, Office 

of Enforcement and Compliance Assurance. 

[FR Doc. 2021–03489 Filed 2–19–21; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL ELECTION COMMISSION 

Sunshine Act Meetings 

TIME AND DATE: Thursday, February 25, 

2021 at 10:00 a.m. 

PLACE: Virtual hearing. Note: Because of 

the covid-19 pandemic, we will conduct 

the hearing virtually. If you would like 

to access the hearing, see the 

instructions below. 

STATUS: This hearing will be open to the 

public. To access the virtual hearing, go 

to the commission’s website 

www.fec.gov and click on the banner to 

be taken to the hearing page. 

MATTERS TO BE CONSIDERED: Repayment 

Hearing: Jill Stein for President. 

CONTACT PERSON FOR MORE INFORMATION: 

Judith Ingram, Press Officer. Telephone: 

(202) 694–1220. 

Authority: Government in the Sunshine 

Act, 5 U.S.C. 552b. 

Laura E. Sinram, 

Acting Secretary and Clerk of the 

Commission. 

[FR Doc. 2021–03692 Filed 2–18–21; 4:15 pm] 

BILLING CODE 6715–01–P 

FEDERAL ELECTION COMMISSION 

Sunshine Act Meetings 

TIME AND DATE: Thursday, February 25, 

2021 following the conclusion of the 

repayment hearing. 

PLACE: Virtual meeting. Note: Because of 

the covid-19 pandemic, we will conduct 

the open meeting virtually. If you would 

like to access the meeting, see the 

instructions below. 

STATUS: This meeting will be open to the 

public. To access the virtual meeting, go 

to the commission’s website 

www.fec.gov and click on the banner to 

be taken to the meeting page. 

MATTERS TO BE CONSIDERED: 

Draft Advisory Opinion 2021–02: Full 

Employment Now-Political Action 

Committee (FEC–PAC) 

Draft Advisory Opinion 2021–03: 

National Republican Senatorial 

Committee (NRSC) and National 

Republican Congressional Committee 

(NRCC) 

Audit Division Recommendation 

Memorandum on Dr. Raul Ruiz for 

Congress (A19–03) 

Management and Administrative 

Matters 

CONTACT PERSON FOR MORE INFORMATION: 

Judith Ingram, Press Officer. Telephone: 

(202) 694–1220. 

Authority: Government in the Sunshine 

Act, 5 U.S.C. 552b 

Laura E. Sinram, 

Acting Secretary and Clerk of the 

Commission. 

[FR Doc. 2021–03694 Filed 2–18–21; 4:15 pm] 

BILLING CODE 6715–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2020–N–1652] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Dispute Resolution 

Procedures for Science-Based 

Decisions on Products by the Center 

for Veterinary Medicine 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, Agency, or we) is 

announcing that a proposed collection 

of information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Submit written comments 

(including recommendations) on the 

collection of information by March 24, 

2021. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be submitted to https://

www.reginfo.gov/public/do/PRAMain. 

Find this particular information 

collection by selecting ‘‘Currently under 

Review—Open for Public Comments’’ or 

by using the search function. The OMB 

control number for this information 

collection is 0910–0566. Also include 

the FDA docket number found in 

brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: Ila 

S. Mizrachi, Office of Operations, Food 

and Drug Administration, Three White 

Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–7726, PRAStaff@

fda.hhs.gov. 


tkelley on DSKBCP9HB2PROD with NOTICES
10582 Federal Register / Vol. 86, No. 33 / Monday, February 22, 2021 / Notices 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Dispute Resolution Procedures for 

Science-Based Decisions on Products by 

the Center for Veterinary Medicine—21 

CFR 10.75 

OMB Control Number 0910–0566— 

Extension 

The Center for Veterinary Medicine 

(CVM) Guidance for Industry (GFI) #79, 

‘‘Dispute Resolution Procedures for 

Science-Based Decisions on Products 

Regulated by the Center for Veterinary 

Medicine’’ (https://www.fda.gov/media/ 

70279/download), describes the process 

by which CVM formally resolves 

disputes relating to scientific 

controversies. A scientific controversy 

involves issues concerning a specific 

product regulated by CVM related to 

matters of technical expertise and 

requires specialized education, training, 

or experience to be understood and 

resolved. The guidance details 

information on how CVM intends to 

apply provisions of existing regulations 

regarding internal review of Agency 

decisions. In addition, the guidance 

outlines the established procedures for 

persons who are sponsors, applicants, or 

manufacturers of animal drugs or other 

products regulated by CVM who wish to 

submit a request for review of a 

scientific dispute. When a sponsor, 

applicant, or manufacturer has a 

scientific disagreement with a written 

decision by CVM, they may submit a 

request for a review of that decision by 

following the established procedures 

discussed in the guidance. 

CVM encourages applicants to begin 

the resolution of science-based disputes 

with discussions with the review team/ 

group, including the Team Leader or 

Division Director. The Center prefers 

that differences of opinion regarding 

science or science-based policy be 

resolved between the review team/group 

and the applicant. If the matter is not 

resolved by this preferred method, then 

CVM recommends that the applicant 

follow the procedures found in GFI #79. 

In the Federal Register of August 18, 

2020 (85 FR 50827), FDA published a 

60-day notice requesting public 

comment on the proposed collection of 

information. No comments were 

received. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR part; activity Number of 

respondents 

Number of 

responses per 

respondent 

Total 

annual 

responses 

Average 

burden per 

response 

Total 

hours 

10.75, Request for review of a scientific dispute ................ 1 4 4 10 40 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

We note that the 60-day notice 

included an inadvertent error in the 

estimated burden, which has been 

corrected in table 1. Based on a review 

of the information collection since our 

last request for OMB approval, we have 

made no adjustments to our burden 

estimate. 

Dated: February 11, 2021. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2021–03431 Filed 2–19–21; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–N–6931] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Current Good 

Manufacturing Practices and Related 

Regulations for Blood and Blood 

Components; and Requirements for 

Donation Testing, Donor Notification, 

and ‘‘Lookback’’ 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, Agency, or we) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on the collection of 

information requirements relating to 

FDA’s regulation of current good 

manufacturing practice (CGMP) and 

related regulations for blood and blood 

components; and requirements for 

donation testing, donor notification, and 

‘‘lookback’’. 

DATES: Submit either electronic or 

written comments on the collection of 

information by April 23, 2021. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before April 23, 

2021. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of April 23, 2021. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 


tkelley on DSKBCP9HB2PROD with NOTICES